Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coeptis Therapeutics Holdings, Inc. (COEP : NSDQ)

• Company Description    Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp., is based in WEXFORD, Pa. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $13.01 Daily Weekly Monthly 20 Day Moving Average: 43,875 shares Shares Outstanding: 4.82 (millions) Market Capitalization: $62.71 (millions) Beta: -0.57 52 Week High: $14.70 52 Week Low: $2.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.33% 11.34% 12 Week 68.52% 53.08% Year To Date 136.55% 101.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 105 BRADFORD ROAD SUITE 420 - WEXFORD,PA 15090 USA ph: 724-934-6467 fax: - ir@coeptistx.com https://coeptistx.com

• General Corporate Information    Officers David Mehalick - Chief Executive Officer; Chairman and President Daniel Yerace - Director and Vice President of Operations Brian Cogley - Chief Financial Officer Christine Sheehy - Vice President of Compliance and Secretary Christopher Calise - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19207A207 SIC: 6199 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 4.82 Most Recent Split Date: 12.00 (0.05:1) Beta: -0.57 Market Capitalization: $62.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.66 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 26.88% vs. Previous Quarter: -5.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 219.05% ROE 06/30/25 - -201.73 03/31/25 - -282.39 12/31/24 - -588.10 ROA 06/30/25 - -108.46 03/31/25 - -127.23 12/31/24 - -167.62 Current Ratio 06/30/25 - 0.83 03/31/25 - 0.82 12/31/24 - 0.23 Quick Ratio 06/30/25 - 0.83 03/31/25 - 0.82 12/31/24 - 0.23 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -4,771.59 03/31/25 - -17,931.75 12/31/24 - - Book Value 06/30/25 - 1.70 03/31/25 - 2.22 12/31/24 - 1.61 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.02 03/31/25 - 0.02 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - 2.07 03/31/25 - 1.97 12/31/24 - 3.73

Powered by Zacks Investment Research ©